LQ058
/ Novamab Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
A novel nanobody based IL-18 surrogate cytokine agonist, used alone or combined with immune checkpoint inhibitors, demonstrated synergistic tumor suppression
(AACR 2025)
- "Besides, LQ058 is designed to have extended half-life which would improve medication convenience. Overall, these positive characteristics of LQ058 make it a promising therapy possible to overcome the limitations of current IL-18 therapies for malignant tumor treatment."
Checkpoint inhibition • Oncology • Solid Tumor • CD8 • IFNG • IL18
1 to 1
Of
1
Go to page
1